Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.54 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12326411 | 0.86 | CYP11B1 (0.55) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL16604315 | 0.86 | CYP11B1 (0.55) | TRPV4CYP11B1CYP11B2 | |
| Formic Acid Methyl Ester SCHEMBL28324376 | 0.86 | CYP11B1 (0.44) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL12012339 | 0.84 | CYP11B1 (0.66) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL253758 | 0.82 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL14228701 | 0.82 | CYP11B1 (0.59) | CYP11B1CYP11B2AR | |
| SCHEMBL22563167 | 0.82 | PGR (0.42) | TRPV4CYP11B1CYP11B2EGLN2 | |
| SCHEMBL9293782 | 0.81 | CYP11B1 (0.50) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL16604328 | 0.80 | CYP11B1 (0.50) | CYP11B1CYP11B2 | |
| SCHEMBL8265080 | 0.79 | CYP11B1 (0.65) | CYP11B1CYP11B2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099777-A1 | METHOD OF UNDERWATER BONDING | Henkel IP & Holding GmbH (DE) | 2023-06-08 | — | — | WO | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-20250338848-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| CN-119768407-A | Protein phosphatase agonist and application thereof | 南京中瑞药业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | BOEHRINGER INGELHEIM INT (DE) | 2025-03-27 | — | — | US | disclosed |
| CN-119661371-A | Preparation method of 2-fluoro-4-methylaniline | 帕潘纳(北京)科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-1030682-C | Method for preparating N-aryl-3-aryl-4.5-dihydro-IH-pyrazole-l-carboxamides | ROHM AND HASS CORP (US) | 1996-01-17 | — | — | CN | disclosed |
| US-5340497-A | Ferroelectric liquid crystal | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-08-23 | — | — | US | disclosed |
| US-4784471-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0211876-A1 | FLUOROBENZENE DERIVATIVES | MERCK PATENT GmbH (DE) | 1987-03-04 | — | — | EP | disclosed |
| WO-1986004895-A1 | FLUOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-08-28 | — | — | WO | disclosed |
| CN-85101497-A | Process for the preparation of N-aryl-3-aryl-4, 5-dihydro-1H-pyrazole-1-carboxamides | — | 1986-07-16 | — | — | CN | disclosed |
| EP-0061907-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1984-08-01 | — | — | EP | disclosed |
| EP-0061907-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | TRPV4 1346/4885CYP11B1 796/4885CYP11B2 786/4885 |
| US-20250338848-A1 | FUNGICIDAL COMPOSITIONS | CYP3A7, DHCR7, CASP7 | TRPV4 2822/4885CYP11B1 251/4885CYP11B2 328/4885 |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | TRPV4 4000/4885CYP11B1 4034/4885CYP11B2 4172/4885 |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | SSTR4, SSTR5, SSTR2 | TRPV4 250/4885CYP11B1 816/4885CYP11B2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.